Connection
Christine Walsh to Poly(ADP-ribose) Polymerase Inhibitors
This is a "connection" page, showing publications Christine Walsh has written about Poly(ADP-ribose) Polymerase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.207 |
|
|
|
-
Walsh C. Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer. Clin Obstet Gynecol. 2024 Dec 01; 67(4):711-719.
Score: 0.805
-
Walsh C. Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. Minerva Ginecol. 2018 Apr; 70(2):150-170.
Score: 0.497
-
Walsh CS, Hodeib M. Leveraging DNA repair deficiency in gynecologic oncology. Curr Opin Obstet Gynecol. 2016 Feb; 28(1):24-31.
Score: 0.442
-
Walsh C, Cass I. Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk-Clues to a Mechanistic Connection? JAMA Oncol. 2021 12 01; 7(12):1763-1765.
Score: 0.166
-
Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, Moore KN, Muller C, Rodriguez P, Walsh C, Westin SN, Kohn EC. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 10 20; 38(30):3468-3493.
Score: 0.151
-
Walsh CS. Latest clinical evidence of maintenance therapy in ovarian cancer. Curr Opin Obstet Gynecol. 2020 02; 32(1):15-21.
Score: 0.146